News

FDA Approval

FDA Approves Selpercatinib for Adult and Pediatric Patients With Advanced or Metastatic Medullary Thyroid Cancer

09/27/2024

Based on results from the phase 3 LIBRETTO-531 study, the FDA has granted traditional approval to selpercatinib for adult and pediatric patients 2 years and older with advanced or metastatic medullary thyroid cancer harboring a RET mutation.

Based on results from the phase...

09/27/2024

Oncology

News

FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors

06/14/2024

Stephanie Holland

Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.

Based on results from the phase...

06/14/2024

Oncology

FDA Approval

FDA Approves Selpercatinib for Adult and Pediatric Patients With RET Fusion-Positive Thyroid Cancer

06/13/2024

Stephanie Holland

Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are...

Based on results from the...

06/13/2024

Oncology

News

Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status

06/28/2022

Hina M. Porcelli ;

Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.

Findings from a systematic...

06/28/2022

Oncology

News

Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status

06/28/2022

Hina M. Porcelli ;

Findings from a systematic...

06/28/2022

Oncology

News

Air Pollution May Be Linked to Increased Occurrence of Thyroid Cancer

11/08/2021

A case-control study found that there may be a connection between air pollution exposure and an increased occurrence of thyroid cancer.

A case-control study found that...

11/08/2021

Oncology

News

Pralsetinib Shows Promise in Patients with RET-Altered Thyroid Cancer

10/12/2021

Pralsetinib shows high potency and is well-tolerated in patients with RET-altered thyroid cancer, according to data from phase 1/2 of the ARROW trial.

Pralsetinib shows high potency...

10/12/2021

Oncology

News

FDA Approves Cabozantinib for Locally Advanced or Metastatic DTC

09/22/2021

The FDA has approved cabozantinib for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) after the results of the COSMIC-311 trial confirm significantly reduced risk...

The FDA has approved...

09/22/2021

Oncology

News

Lenvatinib Not Effective for Patients With Anaplastic Thyroid Cancer

08/03/2021

Lenvatinib monotherapy showed manageable safety but low activity in patients with anaplastic thyroid cancer.

Lenvatinib monotherapy showed...

08/03/2021

Oncology

News

Cabozantinib Improves PFS in Patients with RAI-Refractory DTC

07/06/2021

Patients with RAI-refractory differentiated thyroid cancer who progressed after previous VEGFR-targeted therapy saw improved survival when treated with cabozantinib.

Patients with RAI-refractory...

07/06/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology